Abstract
Concentrations of the hypoxic cell radiosensitizer misonidazole (MIS) and its O-demethylated metabolite Ro 05-9963 were determined in plasma (or blood), brain and tumour after injection of 1 g/kg MIS i.p. to control mice or mice pretreated with 4-6 daily injections of phenobarbitone or phenytoin. Analysis was by high-performance liquid chromatography (HPLC). Phenobarbitone and phenytoin did not alter the peak MIS concentration in plasma, brain or tumor. However, the apparent elimination half-life (t 1/2) for MIS was reduced by 20-67%, and the area under the curve (AUC) was decreased by 23-49% in plasma, brain and tumour. The decrease in MIS t 1/2 was associated with an initially increased Ro 05-9963 metabolite concentration. However, the AUC for total 2-nitromidazole (MIS + Ro 05-9963) in plasma, tumour and brain was reduced by 20-50%. Urinary excretion of MIS and its metabolites accounted for 15-42% of the injected dose, and was unaltered by pretreatment with phenobarbitone or phenytoin. Tumour/plasm and brain/plasma concentration ratios for MIS, and tumour/plasma ratios for Ro 05-9963 were very similar, but the brain/tumour ratios for Ro 05-9963 were considerably lower. Tissue/plasma ratios were unaltered by pretreatment with phenobarbitone or phenytoin. The acute LD50 for MIS was increased from 1.54 to 1.90 g/kg after phenobarbitone pretreatment and 1.78 g/kg after phenytoin pretreatment. In addition, pretreatment with either compound shortened the duration of the MIS-induced decrease in body temperature. These data suggest that pretreatment with microsomal-enzyme-inducing agents may reduce the toxicity of MIS without affecting the radiosensitization. The significance of these findings for the mechanism of MIS toxicity is also discussed.
Highlights
Summary.-Concentrations of the hypoxic cell radiosensitizer misonidazole (MIS) and its 0 -demethylated metabolite Ro 05 -9963 were determined in plasma, brain and tumour after injection of I g/kg MIS i.p. to control mice or mice pretreated with 4-6 daily injections of phenobarbitone or phenytoin
In the present paper we describe an investigation of the effects of phenobarbitone and phenytoin pretreatment on the pharmacokinetics and toxicity of MIIS in mice
C'oncentrations of MIS and the metabolite Ro 05-9963 were determined in tumour, brain and plasma of mice pretreated with phenobarbitone, plhenytoin or vehicle alone
Summary
Summary.-Concentrations of the hypoxic cell radiosensitizer misonidazole (MIS) and its 0 -demethylated metabolite Ro 05 -9963 were determined in plasma (or blood), brain and tumour after injection of I g/kg MIS i.p. to control mice or mice pretreated with 4-6 daily injections of phenobarbitone or phenytoin. Phenobarbitone and phenytoin did not alter the peak MIS concentration in plasma, brain or tumour. In the present paper we describe an investigation of the effects of phenobarbitone and phenytoin pretreatment on the pharmacokinetics and toxicity of MIIS in mice. Mice wvere used 9 days after inoculation, -when their tumours were in the same size range as the EMT6 tumours For both the MC6B and EMT6 tumours, tumour volumes in mice pretreated with phenobarbitone or phenytoin were often up to 10% lower than the saline controls, but this was usually not significant (P > 0 05). Sodium pentobarbitone was obtained from May & Baker Limited (Dagenhanm) as a 60 mg/ml solution for injection (Sagatal)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
